ARTICLE | Clinical News
Amarillo's interferon disappoints in Phase III
April 7, 2000 7:00 AM UTC
AMAR said that its 24-week, 241-patient U.S. trial of oral interferon alpha to treat primary Sjogren's syndrome did not meet its primary end point of increasing stimulated whole saliva production and reduction in subjective oral dryness. However, oral interferon did produce a significant improvement in unstimulated whole saliva production that correlated with subjective improvements in oral dryness, throat dryness and nasal dryness. AMAR was down $0.875 (23 percent) to $2.875 on Friday. ...